1. INTRODUCTION
===============

Lung cancer remains the leading cause of cancer-related death in both women and men in Canada and throughout the world [@b1-co15-6-279],[@b2-co15-6-279]. The estimated 24,000 Canadians who will be diagnosed with lung cancer in 2008 face a 5-year relative survival rate of 15% [@b1-co15-6-279]. Current survival rates reflect modest advances in anticancer therapies, considering the 5% average 5-year survival rate of the 1960s.

Non-small-cell lung cancer ([nsclc]{.smallcaps}) is the most common and deadly form of lung cancer [@b3-co15-6-279]. The current standard of care for patients with locally advanced or metastatic [nsclc]{.smallcaps} and adequate performance status ([ps]{.smallcaps}) involves up to 3 lines of systemic therapy. Platinum-based combination chemotherapy is recognized as the first-line standard of care in [nsclc]{.smallcaps}[@b4-co15-6-279]. Upon failure of first-line therapy, 3 treatment options currently exist for second- and subsequent-line therapy ([Table I](#tI-co15-6-279){ref-type="table"}). Docetaxel (Taxotere: Sanofi-Aventis Canada, Laval, QC) was the first cytotoxic agent approved for the second-line treatment of advanced [nsclc]{.smallcaps} based on phase [iii]{.smallcaps} trials showing a longer survival than that seen with with best supportive care ([bsc]{.smallcaps})[@b6-co15-6-279]. Erlotinib (Tarceva: Hoffmann--La Roche Ltd., Mississauga, ON), an epidermal growth factor receptor tyrosine kinase inhibitor ([egfr]{.smallcaps}-[tki]{.smallcaps}), was approved in Canada in 2005 as monotherapy for the treatment of patients with metastatic [nsclc]{.smallcaps} after failure of at least 1 prior chemotherapy regimen [@b11-co15-6-279]. Erlotinib demonstrated survival improvement in addition to control of the most distressing lung cancer symptoms and improvement in quality of life ([qol]{.smallcaps}). The phase [iii jmei]{.smallcaps} trial [@b7-co15-6-279] (*n* = 571) demonstrated that the clinical efficacy of pemetrexed (Alimta: Eli Lilly Canada, Toronto, ON) was equivalent to that of docetaxel, therefore making pemetrexed a third option for therapy in recurrent [nsclc]{.smallcaps}.

Epidermal growth factor receptor is overexpressed in approximately 80% of [nsclc]{.smallcaps} cases, making it an ideal therapeutic target [@b12-co15-6-279]. As an [egfr]{.smallcaps}-[tki]{.smallcaps}, erlotinib competes with [atp]{.smallcaps} for the catalytic binding site of the [egfr]{.smallcaps} tyrosine kinase inside tumour cells, thus inhibiting [egfr]{.smallcaps} autophosphorylation and subsequent downstream signalling[@b13-co15-6-279]. Agents that target [egfr]{.smallcaps} spare healthy cells by selectively inhibiting specific pathways involved in tumour growth and progression, resulting in a favourable safety profile as compared with chemotherapeutic agents [@b14-co15-6-279].

Several trials have demonstrated the activity of [egfr]{.smallcaps}-[tkis]{.smallcaps} in recurrent [nsclc]{.smallcaps}. The phase [iii]{.smallcaps} National Cancer Institute of Canada [br]{.smallcaps}.21 trial [@b8-co15-6-279] (*n* = 731) compared erlotinib with [bsc]{.smallcaps} in patients with advanced [nsclc]{.smallcaps} who had received 1 or 2 regimens of chemotherapy and who were not eligible for further chemotherapy. Half of the patients in the trial were treated with erlotinib as second-line therapy, and half received erlotinib as third-line therapy. As compared with [bsc]{.smallcaps}, treatment with erlotinib resulted in significantly longer overall survival \[6.7 months vs. 4.7 months; hazard ratio ([hr]{.smallcaps}): 0.70; *p* \< 0.001\] and significantly higher progression-free survival favouring erlotinib (2.2 months vs. 1.8 months; [hr]{.smallcaps}: 0.6; *p* \< 0.001). Patients who received erlotinib also demonstrated significantly longer stability of their lung cancer-related symptoms (dyspnea, pain, and cough), superior [qol]{.smallcaps}, and improved physical function as compared with patients in the placebo arm.

The subgroups with a greater likelihood of a response to erlotinib have been widely catalogued, but a multivariate analysis revealed that a non-smoking history was the only significant independent predictor of a survival effect with erlotinib [@b15-co15-6-279]. Never smokers receiving erlotinib had a significantly higher survival rate than did patients in the placebo arm ([hr]{.smallcaps}: 0.4; *p* \< 0.01).

Docetaxel, erlotinib, and pemetrexed have significantly changed the treatment landscape for advanced [nsclc]{.smallcaps}, but the optimal selection of second-line (and subsequent third-line) therapy has yet to be firmly established. A variety of factors, such as the divergent toxicity profiles of the agents and the lack of well-defined prognostic patient characteristics, combine to confound treatment decisions in recurrent [nsclc]{.smallcaps}. Following first-line trials that showed no increased efficacy of concomitant [egfr]{.smallcaps}-[tki]{.smallcaps} and chemotherapy treatment over chemotherapy alone [@b16-co15-6-279]--[@b19-co15-6-279], it was proposed that these two types of agents are antagonistic when given concurrently; specifically, [egfr]{.smallcaps}-[tkis]{.smallcaps} may interfere with the cell cycle--specific cytotoxicity of chemotherapy agents [@b20-co15-6-279],[@b21-co15-6-279].

These data led to some debate over the effectiveness of third-line chemotherapy following second-line [egfr]{.smallcaps}-[tki]{.smallcaps} treatment, but studies have demonstrated that chemotherapy can indeed be used effectively when preceded by [egfr]{.smallcaps}-[tkis]{.smallcaps}. For example, the recent trial multinational [interest]{.smallcaps}[@b22-co15-6-279] (*n* = 1316) demonstrated that second-line therapy with gefitinib in an unselected population provided a survival improvement similar to that of second-line chemotherapy, with a significant number of patients going on to successfully receive third-line chemotherapy. In a phase [ii]{.smallcaps} study of erlotinib in untreated patients, Giaccone *et al.* also reported that most patients went on to receive subsequent treatment with chemotherapy [@b23-co15-6-279].

Given the similar efficacies of docetaxel, erlotinib, and pemetrexed, the incurable nature of advanced [nsclc]{.smallcaps}, and the clinically relevant survival seen in the second-line setting, clinicians must weigh a variety of factors when selecting second- and third-line treatment. The purpose of this retrospective practice review was to examine the outcomes of second-line erlotinib treatment followed by third-line chemotherapy in the treatment of recurrent metastatic [nsclc]{.smallcaps} in Canadian clinical practice.

2. METHODS
==========

For this retrospective chart review, we identified patients with recurrent [nsclc]{.smallcaps} who had received second-line erlotinib therapy followed by third-line chemotherapy. Eligible patients were selected by census from three major Canadian cancer treatment centres. All patients had failed prior systemic cytotoxic therapy and therefore detailed first-line data are not included in this analysis.

Clinicopathologic demographics collected from patient medical records were age, ethnicity, sex, [nsclc]{.smallcaps} pathology (adenocarcinoma, bronchioalveolar, squamous, large-cell, [nsclc]{.smallcaps} not otherwise specified), tumour [egfr]{.smallcaps} status (positive, negative, unknown), smoking history (current/ever smoker, never smoker), and [ps]{.smallcaps} \[Eastern Cooperative Oncology Group ([ecog]{.smallcaps}) 0--3\] [@b24-co15-6-279]. First-, second-, and third-line treatment data collected included the type of treatment, reason for selecting the agent, time to progression ([ttp]{.smallcaps}), best response \[progressive disease ([pd]{.smallcaps}), stable disease ([sd]{.smallcaps}), partial response ([pr]{.smallcaps}), complete response ([cr]{.smallcaps})\], number of cycles delivered, dose reductions and delays, reason for discontinuation, dose intensity, cancer-related hospitalizations, and date of death. The presence, onset, grade, and resolution of rash during erlotinib treatment were also recorded. Criteria used for classifying response and progression included the Response Evaluation Criteria in Solid Tumors [@b25-co15-6-279], radiographs, and computed tomography or bone scans.

The study was approved by the ethics committees and health records departments at all institutions involved. Because the study was an observational, retrospective case series, power estimation and analyses for statistical significance were not performed. Demographic, treatment, and outcome data are summarized.

3. RESULTS
==========

We identified 35 patients with advanced [nsclc]{.smallcaps} for this retrospective practice review. Selected study subjects received second-line erlotinib therapy followed by third-line chemotherapy in the period between March 2001 and April 2008. Patient data was collected from three Canadian institutions: the BC Cancer Agency, Vancouver, British Columbia (*n* = 16); the Jewish General Hospital, Montreal, Quebec (*n* = 16); and The Moncton Hospital, Moncton, New Brunswick (*n* = 3).

The study population was evenly split between the sexes and had a median age of 59 years. Most of the patients were white (66%), but Asian patients accounted for 31% of the study population. The most commonly reported pathology was adenocarcinoma (72%), and most of the patients had an [ecog]{.smallcaps} performance status of 1 (69%) at the time of metastatic diagnosis. The proportion of current/ever smokers closely matched the proportion of never smokers in this population. [Table II](#tII-co15-6-279){ref-type="table"} presents baseline patient demographics.

3.1 First-Line Therapy
----------------------

Of the 35 study patients, 97% received standard platinum-doublet first-line therapy for advanced [nsclc]{.smallcaps}. First-line regimens varied by centre; the most common doublets were cisplatin--gemcitabine (26% of patients), carboplatin--paclitaxel (23%), and carboplatin--gemcitabine (20%). The calculated mean first-line [ttp]{.smallcaps} of 6.6 months and 46% overall response rate (1 [cr]{.smallcaps} and 15 [prs]{.smallcaps}) suggest that the study population benefited as expected from treatment in this setting.

3.2 Second-Line Erlotinib Therapy
---------------------------------

All 35 patients received second-line erlotinib treatment after failing or being unable to tolerate first-line chemotherapy. Patients were initiated on the standard dose of 150 mg once daily. In 89% of the patients, no dose reductions or delays were required throughout second-line treatment. Patients requiring dose reductions (*n* = 3) maintained a median dose intensity of 87%. The average duration of erlotinib treatment was 9.2 months and the median [ttp]{.smallcaps} was 7 months. Based on best response in the second line, 40% of patients experienced a [pr]{.smallcaps}, 26% had [sd]{.smallcaps}, and 34% had [pd]{.smallcaps}. [Table III](#tIII-co15-6-279){ref-type="table"} summarizes [ttp]{.smallcaps} results for second- and third-line therapy.

3.3 Third-Line Therapy
----------------------

Of the 35 patients who received second-line erlotinib, 34 went on to receive third-line single-agent chemotherapy, and 1 went on to receive the [egfr]{.smallcaps}-[tki]{.smallcaps} gefitinib. The most common third-line agent was docetaxel (53%), followed by pemetrexed (24%), gemcitabine (12%), and vinorelbine (9%). According to records of best response during third-line therapy, 18% of patients exhibited a [pr]{.smallcaps}, 50% maintained [sd]{.smallcaps}, and 32% experienced [pd]{.smallcaps}. As expected, the mean third-line [ttp]{.smallcaps} of 4.3 months was the lowest of all lines of therapy. [Table III](#tIII-co15-6-279){ref-type="table"} compares key efficacy parameters for second- and third-line therapy, including [ttp]{.smallcaps}, best response, and [ps]{.smallcaps} before therapy.

3.4 Populations of Interest
---------------------------

Further analysis of patient data identified populations of interest that demonstrated improved [ttp]{.smallcaps} with second- line erlotinib therapy. First, improved outcomes were observed in the two thirds of patients who developed rash subsequent to erlotinib treatment. The mean [ttp]{.smallcaps} was 10.5 months for patients with rash as compared with 5.8 months in patients without rash. Patients who developed rash were also much more likely to experience a [pr]{.smallcaps} to second-line erlotinib treatment (54%) than were those without rash (9%). In addition, increasing [ttp]{.smallcaps} was positively associated with increasing grade of rash severity. [Table IV](#tIV-co15-6-279){ref-type="table"} summarizes outcomes in patients who developed a rash as compared with patients who did not. These results are consistent with larger controlled trials of erlotinib for [nsclc]{.smallcaps} that have demonstrated a positive correlation between rash and response or survival [@b16-co15-6-279],[@b19-co15-6-279],[@b26-co15-6-279],[@b27-co15-6-279]. [Figure 1](#f1-co15-6-279){ref-type="fig"} shows the Kaplan--Meier estimate of time to progression by grade of rash. All patients in this practice review that benefited beyond 10 months developed rash secondary to erlotinib treatment. All rashes were mild-to-moderate in severity. Treatment varied across centres; however, all rashes resolved completely.

Never smokers also demonstrated improved outcomes with second-line erlotinib. The mean [ttp]{.smallcaps} of never smokers was 12.3 months, as compared with 5.6 months for current/ever smokers. Never smokers were also much more likely to experience a [pr]{.smallcaps} to second-line erlotinib treatment (63%) than were current/ever smokers (13%). [Table V](#tV-co15-6-279){ref-type="table"} summarizes patient outcomes according to smoking history. These results are consistent with larger controlled trials of erlotinib in advanced [nsclc]{.smallcaps}. An exploratory multivariate analysis of the [br]{.smallcaps}.21 study revealed that a history of never smoking was predictive both of response to erlotinib and of survival ([hr]{.smallcaps}: 0.8; *p* = 0.004) [@b8-co15-6-279].

Further analyses of this study population demonstrated that female sex and Asian race also conferred improvements in [ttp]{.smallcaps} with second-line erlotinib therapy as compared with male sex and non-Asian race respectively. However, it should be noted that the current/ever smoker, male, and non-Asian subgroups also did better in this review than in previous reports. Our findings align with analyses from controlled trials, such as the [br]{.smallcaps}.21 trial, demonstrating that all patient subgroups benefit from erlotinib treatment, and that patients with certain defined clinical characteristics may do better than the average seen for all second-line agents [@b8-co15-6-279]. We also calculated and compared TTP for EGFR-positive and EGFR-negative patients; however, mutational status was unknown for 77% of the study population. [Table VI](#tVI-co15-6-279){ref-type="table"} summarizes [ttp]{.smallcaps} with second-line erlotinib therapy in populations of interest. [Figure 2](#f2-co15-6-279){ref-type="fig"} compares median second-line [ttp]{.smallcaps} values for the populations of interest mentioned here.

4. DISCUSSION
=============

The small size and retrospective nature of this case series limits the findings of this analysis of second-line erlotinib in [nsclc]{.smallcaps} patients. In 50% of cases, investigators cited clinical characteristics associated with increased response (for example, female sex, Asian race, positive [egfr]{.smallcaps} mutational status, non-smoking history) as the reason for prescribing erlotinib in the second-line setting. This patient selection bias is reflected in the overall patient demographics: more than half the patients enrolled were women, 72% had adenocarcinoma, 31% were Asian, and 54% were never smokers. This patient selection bias may account for the high [ttp]{.smallcaps} and response rate observed in this analysis. However, the median age of 59 years in this study is similar to the median age in the pivotal phase [iii]{.smallcaps} second- and subsequent-line advanced [nsclc]{.smallcaps} trials (61, 58, and 62 years respectively) [@b6-co15-6-279],[@b12-co15-6-279],[@b15-co15-6-279]. The proportion of patients with [ps]{.smallcaps} 0 or 1 in this study (73%) is also comparable to the large pivotal trials (76%, 88%, and 66% respectively) [@b6-co15-6-279],[@b7-co15-6-279],[@b8-co15-6-279].

The mean first-line [ttp]{.smallcaps} of 6.6 months and response rate of 46% (15 [pr]{.smallcaps}; 1 [cr]{.smallcaps}) with platinum-doublet therapy suggests that the study population benefited as expected (or better) in this setting as compared with previous trials. Investigators indicated most often that chemotherapy was discontinued because of completion of therapy (49%), no response or progression (17%), and because of toxicity such as febrile neutropenia, thrombocytopenia, deep vein thrombosis, fatigue, and peripheral neuropathology (17%).

In the second-line setting, the study population demonstrated benefit from second-line erlotinib treatment in advanced [nsclc]{.smallcaps}. The median overall [ttp]{.smallcaps} of 7.0 months and the response rate of 40% with second-line erlotinib treatment in this study were greater than those reported in the pivotal phase [iii]{.smallcaps} studies examining outcomes in the second-line treatment of advanced [nsclc]{.smallcaps} [@b6-co15-6-279],[@b7-co15-6-279],[@b8-co15-6-279]. In our analysis, dose intensity was well maintained throughout second-line treatment, with only 3 patients requiring dose reductions. Erlotinib was well tolerated, with an average duration of treatment of 9.2 months. Investigators cited progression as the rationale for 88% of cases in which erlotinib was discontinued. Side effects, including gastrointestinal symptoms, were the reason for 12% of erlotinib discontinuations. In 5 patients, hospitalization occurred for cancer-related reasons. Clinicians noted symptom improvement in 23% of patients during second-line erlotinib treatment. In 13% of patients, [ps]{.smallcaps} improved; it remained stable in 50%; and it worsened in 37% of patients.

Third-line chemotherapy in this case series involved many different agents, including docetaxel (most commonly used), pemetrexed, gemcitabine, and vinorelbine. Third-line therapy following erlotinib was observed to be effective in this analysis, with a median [ttp]{.smallcaps} of 3.5 months and an overall response rate of 18%. These results compare closely to third-line results observed by Ng *et al.* in a similar Canadian retrospective review [@b28-co15-6-279] (*n* = 21): for docetaxel, median [ttp]{.smallcaps} was 4.2 months with a 5% response rate.

Median time to death after discontinuation of third-line chemotherapy in the present case series was 5.4 months. Four patients are still receiving third-line chemotherapy, and 2 patients are currently receiving fourth-line therapy with docetaxel.

Our data demonstrate that metastatic [nsclc]{.smallcaps} patients who are able to receive third-line chemotherapy following second-line erlotinib both tolerate it and benefit from it. In the present study, we observed greater response rates and [ttp]{.smallcaps} from second-line therapy than has previously been reported in controlled trials. That result may be somewhat an effect of the partially selected population. Another possible explanation for the extended benefit may be clinicians' improved ability to manage patients who develop a skin rash, and thus avoid dose reductions or discontinuations, especially in light of continuing evidence that rash is an indicator of additional benefit to the patient [@b29-co15-6-279],[@b30-co15-6-279].

The results of our case series further support the evidence that it is appropriate to consider 3 lines of treatment in patients with advanced [nsclc]{.smallcaps}. In addition, erlotinib benefits patients in all demographics, and second-line [egfr]{.smallcaps}-[tki]{.smallcaps} followed by chemotherapy is an effective treatment option.

5. CONCLUSIONS
==============

For patients with advanced [nsclc]{.smallcaps} who progress following first-line platinum-based chemotherapy, our retrospective practice review demonstrates that second-line [egfr]{.smallcaps}-[tki]{.smallcaps} treatment with erlotinib is efficacious and well tolerated. In addition, second-line erlotinib treatment does not appear to diminish benefit from subsequent third-line chemotherapy. And although certain patient subgroups exhibited improved [ttp]{.smallcaps} during second-line therapy, patients without the clinical characteristics associated with increased response to [egfr]{.smallcaps}-[tki]{.smallcaps}s also demonstrated benefit from erlotinib treatment.

Three lines of therapy should be considered for patients with metastatic [nsclc]{.smallcaps}. Choice of second-line and subsequent therapy should be individualized based on numerous considerations such as symptom improvement, [ps]{.smallcaps}, patient comorbidities, toxicity, [qol]{.smallcaps} considerations, patient preference, convenience, and ease of administration.
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###### 

Results of selected randomized phase [iii]{.smallcaps} trials in the second-line treatment of non-small-cell lung cancer

  Reference                                                         Agents                                                                                Patients (*n*)   Arm                               Median cycles (*n*)                              Response rate (%)   Median survival (mo.)   1-Year survival (%)   2-Year survival (%)                             Median survival (mo.) for [ps]{.smallcaps} 0 or 1 in second line
  ----------------------------------------------------------------- ------------------------------------------------------------------------------------- ---------------- --------------------------------- ------------------------------------------------ ------------------- ----------------------- --------------------- ----------------------------------------------- ------------------------------------------------------------------
  Fossella *et al.*, 2000 [@b5-co15-6-279] ([tax]{.smallcaps}320)   Docetaxel compared with vinorelbine or ifosfamide ([v]{.smallcaps}/[i]{.smallcaps})   373              D100                              3                                                10.8                5.5                     21                                                                    
                                                                                                                                                                           D75                               3                                                6.7                 5.7                     32                    [na]{.smallcaps}                                [na]{.smallcaps}
                                                                                                                                                                           [v]{.smallcaps}/[i]{.smallcaps}   3/2                                              0.8                 5.6                     19                                                                    
  Shepherd *et al.*, 2000[@b6-co15-6-279] ([tax]{.smallcaps}317)    Docetaxel compared with best supportive care ([bsc]{.smallcaps})                      104              D100                              2                                                7.1                 5.9                     19                                                                    [na]{.smallcaps}
                                                                                                                                                                           D75                               4                                                7.1                 7.5                     37                    [na]{.smallcaps}                                7.9
                                                                                                                                                                           [bsc]{.smallcaps}                 ---                                              ---                 4.6                     11                                                                    6.3
  Hanna *et al.*, 2004 [@b7-co15-6-279] ([jmei]{.smallcaps})        Docetaxel compared with pemetrexed                                                    571              D75                               4                                                8.8                 7.9                     29.7                  0                                               9.1
                                                                                                                                                                           Pem                               4                                                9.1                 8.3                     29.7                  0                                               9.4
  Shepherd *et al.*, 2005 [@b8-co15-6-279] ([br]{.smallcaps}.21)    Erlotinib compared with [bsc]{.smallcaps}                                             731              E150                              --- [a](#tfn1-co15-6-279){ref-type="table-fn"}   8.9                 6.7                     31                    13 [b](#tfn2-co15-6-279){ref-type="table-fn"}   9.4
                                                                                                                                                                           [bsc]{.smallcaps}                 ---                                              ---                 4.7                     21                    0                                               6.7

Erlotinib was given until disease progression or unacceptable toxicity.

Personal communication to author.

Adapted from Stinchcombe and Socinski, 2008 [@b9-co15-6-279] and Ramalingam and Sandler, 2006 [@b10-co15-6-279]. [ps]{.smallcaps} = performance status; D100 = docetaxel 100 mg/m[@b2-co15-6-279] every 3 weeks; D75 = docetaxel 75 mg/m[@b2-co15-6-279] every 3 weeks; [na]{.smallcaps} = not available; Pem = pemetrexed 500 mg/m[@b2-co15-6-279] every 3 weeks; E150 = erlotinib 150 mg daily.

###### 

Baseline patient (*n* = 35) characteristics

  *Characteristic*                                                n        *%*
  --------------------------------------------------------------- -------- -----
  Age (years)                                                              
   Median                                                         59       ---
   Range                                                          38--80   ---
  Sex                                                                      
   Male                                                           17       49
   Female                                                         18       51
  Race                                                                     
   Asian                                                          11       31
   White                                                          23       66
   Other                                                          1        3
  [egfr]{.smallcaps} status by mutation                                    
   Positive                                                       3        9
   Negative                                                       5        14
   Unknown                                                        27       77
  Performance status [a](#tfn4-co15-6-279){ref-type="table-fn"}            
   0                                                              5        14
   1                                                              24       69
   2                                                              6        17
  Pathology subtype                                                        
   Adenocarcinoma                                                 25       72
   Squamous cell carcinoma                                        4        11
   Bronchioloalveolar carcinoma                                   1        3
   Large-cell                                                     1        3
   Non-small-cell lung cancer/ not otherwise specified            4        11
  Smoking status                                                           
   Current/ever smoker                                            16       46
   Never smoker                                                   19       54

Eastern Cooperative Oncology Group performance status at metastatic diagnosis.

[egfr]{.smallcaps} = epidermal growth factor receptor.

###### 

Efficacy results for second- and third-line therapy

                                    Second line   Third line        
  --------------------------------- ------------- ------------ ---- -----
  [ttp]{.smallcaps} (months)        *n=*33        *n=*18            
   Mean                             9.2           4.3               
   Median                           7.0           3.5               
   Range                            1.3--28.9     1.2--11.8         
                                                                    
                                    n             *%*          n    *%*
                                                                    
  Best response                     *n=*35        *n=*28            
   Partial response                 14            40           5    18
   Stable disease                   9             26           14   50
   Progressive disease              12            34           9    32
  [ps]{.smallcaps} before therapy   *n=*35        *n=*35            
   0                                9             26           7    20
   1                                18            51           10   28
   2                                7             20           17   49
   3                                1             3            1    3

[ttp]{.smallcaps} = time to progression; [ps]{.smallcaps} = performance status.

###### 

Effect of rash on outcomes with second-line erlotinib therapy

                                                             Rash (*n*=24; 67%)   No rash (*n* =11; 33%)                                                
  ---------------------------------------------------------- -------------------- --------------------------------- ----------------------------------- -----
  [ttp]{.smallcaps} (months)                                                                                                                            
   Mean                                                      10.5                 5.8                                                                   
   Median                                                    8.2                  3.3                                                                   
   Range                                                     2.1--28.9            1.3--13.7                                                             
                                                                                                                                                        
                                                             n                    *%*                               n                                   *%*
                                                                                                                                                        
  Best response                                                                                                                                         
   Partial response                                          13                   54                                1                                   9
   Stable disease                                            6                    25                                3                                   27
   Progressive disease                                       5                    21                                7                                   64
                                                                                                                                                        
                                                             *Patients (*n*)*     *Mean[ttp]{.smallcaps}(months)*   *Median[ttp]{.smallcaps}(months)*   
                                                                                                                                                        
  Grade of rash [a](#tfn7-co15-6-279){ref-type="table-fn"}                                                                                              
   1                                                         7                    9.1                               8.8                                 
   2                                                         13                   10.4                              3.9                                 
   3                                                         4                    13.5                              12.0                                

Grade 1 rash = mild; Grade 2 = moderate; Grade 3 = severe/ intolerable.

[ttp]{.smallcaps} = time to progression.

###### 

Smoking history and second-line erlotinib therapy

                               Never smokers (*n*=19, 54%)   Current/ever smokers (*n*=16, 46%)         
  ---------------------------- ----------------------------- ------------------------------------ ----- ----
  [ttp]{.smallcaps} (months)                                                                            
   Mean                        12.3                          5.6                                        
   Median                      10.4                          3.9                                        
   Range                       2.1--28.9                     1.3--14.0                                  
                                                                                                        
                               *n*                           \%                                   *n*   \%
                                                                                                        
  Best response                                                                                         
   Partial response            12                            63                                   2     13
   Stable disease              5                             26                                   4     25
   Progressive disease         2                             11                                   10    63

[ttp]{.smallcaps} = time to progression.

###### 

Time to progression ([ttp]{.smallcaps}) in populations of interest with second-line erlotinib therapy

  Characteristic                 Patients (*n*)   [ttp]{.smallcaps} (months)   
  ------------------------------ ---------------- ---------------------------- ------
  Total population               35               9.2                          7.0
  Never smokers                  19               12.3                         10.4
  Current/ever smokers           16               5.6                          3.9
  Women                          18               11.1                         9.9
  Men                            17               7.3                          4.2
  Asian                          11               10.2                         10.1
  Non-Asian                      24               8.8                          4.9
  Rash                           24               10.5                         8.2
  No rash                        11               5.8                          3.3
  [egfr]{.smallcaps}-positive    3                10.8                         7.0
  [egfr]{.smallcaps}-negative    5                8.7                          3.7
  Adenocarcinoma histology       25               9.4                          7.6
  Non-adenocarcinoma histology   10               8.9                          3.9

[egfr]{.smallcaps} = epidermal growth factor receptor.
